Crinetics (CRNX) director sells 3,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Stephanie Okey reported an open-market sale of 3,000 shares of common stock at $39.67 per share on March 3, 2026. The trade was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2025, and she now holds 13,300 shares.

Insider Trade Summary

Net Seller: 3,000 shares ($119,010)

Net Sell 1 txn

Insider Okey Stephanie

Role Director

Sold 3,000 shs ($119K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$39.67	$119K

Holdings After Transaction: Common Stock — 13,300 shares (Direct)

Footnotes (1)

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $39.67 per share.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okey Stephanie

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		3,000	D	$39.67(2)	13,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $39.67 per share.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Crinetics (CRNX) report for Stephanie Okey?

Crinetics director Stephanie Okey reported selling 3,000 shares of common stock. The sale occurred on March 3, 2026 at a price of $39.67 per share in open-market transactions, according to the Form 4 filing details.

At what price did Stephanie Okey sell Crinetics (CRNX) shares?

Stephanie Okey sold Crinetics common stock at $39.67 per share. The Form 4 notes these were open-market transactions executed on March 3, 2026, reflecting a single sale price across the 3,000 shares reported.

How many Crinetics (CRNX) shares does Stephanie Okey hold after the sale?

After the reported sale, Stephanie Okey beneficially owns 13,300 Crinetics shares. This post-transaction balance comes directly from the Form 4 and represents her remaining direct ownership following the 3,000-share disposition.

Was the Crinetics (CRNX) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was effected automatically under a Rule 10b5-1 trading plan. That plan was adopted by Stephanie Okey on November 19, 2025, before the March 3, 2026 transaction date disclosed.

What type of transaction did Crinetics (CRNX) disclose for Stephanie Okey?

The filing describes an open-market sale of common stock. It uses transaction code “S,” indicating a sale, and specifies that the 3,000 shares were sold in open-market transactions at $39.67 per share on March 3, 2026.

Is Stephanie Okey a director of Crinetics (CRNX) in this Form 4?

Yes. The Form 4 identifies Stephanie Okey as a director of Crinetics Pharmaceuticals. Her reported transaction involves common stock held directly, with ownership type classified as direct in the filing’s data fields.